دورية أكاديمية
أعرض في EDS

Skeleton density and ellipsoid zone loss are prognostic for progression in Macular Telangiectasia Type 2.

التفاصيل البيبلوغرافية
العنوان: Skeleton density and ellipsoid zone loss are prognostic for progression in Macular Telangiectasia Type 2.
المؤلفون: Goerdt L; Department of Ophthalmology, University Hospital Bonn, Ernst-Abbe-Str 2, 53127, Bonn, Germany.; Department of Ophthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Berger M; Institute for Medical Biometry, Informatics and Epidemiology, Medical Faculty, University of Bonn, Bonn, Germany., Jungblut J; Department of Ophthalmology, University Hospital Bonn, Ernst-Abbe-Str 2, 53127, Bonn, Germany., Rodriguez Garcia JL; Department of Ophthalmology, University Hospital Bonn, Ernst-Abbe-Str 2, 53127, Bonn, Germany., Pfau K; Department of Ophthalmology, University Hospital Bonn, Ernst-Abbe-Str 2, 53127, Bonn, Germany.; Department of Ophthalmology, University Hospital Basel, Basel, Switzerland.; Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland., Herrmann P; Department of Ophthalmology, University Hospital Bonn, Ernst-Abbe-Str 2, 53127, Bonn, Germany., Holz FG; Department of Ophthalmology, University Hospital Bonn, Ernst-Abbe-Str 2, 53127, Bonn, Germany., Wintergerst MWM; Department of Ophthalmology, University Hospital Bonn, Ernst-Abbe-Str 2, 53127, Bonn, Germany. Maximilian.Wintergerst@ukbonn.de.; Augenzentrum Grischun, Chur, Switzerland. Maximilian.Wintergerst@ukbonn.de.
المصدر: Scientific reports [Sci Rep] 2024 Jul 27; Vol. 14 (1), pp. 17328. Date of Electronic Publication: 2024 Jul 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Retinal Telangiectasis*/pathology , Retinal Telangiectasis*/diagnosis , Tomography, Optical Coherence*/methods , Disease Progression*, Humans ; Male ; Female ; Prognosis ; Aged ; Middle Aged ; Visual Acuity ; Retinal Vessels/diagnostic imaging ; Retinal Vessels/pathology ; Retina/pathology ; Retina/diagnostic imaging ; Fluorescein Angiography/methods
مستخلص: Macular Telangiectasia Type 2 (MacTel) is a chronic, progressive disease of the central retina characterized by vascular and neurodegenerative changes. As there is currently no treatment for non-neovascular MacTel, there is a dearth for biomarkers identifying eyes with an increased risk for disease progression for patient counseling and clinical trial recruitment. Eyes were classified to be stable or progressive, defined by the fundus photography-based grading system by Gass and Blodi. First, structural differences between these two groups were assessed, employing optical coherence tomography (OCT) and OCT-angiography. Univariate regression analyses revealed evidence towards a lower superficial retinal layer (SRL) vessel density (VD), skeleton density (SD) and deep retinal layer (DRL) SD in progressing compared to stable eyes (p = 0.05, p = 0.05, p = 0.07). Second, a multivariable predictive model was employed to examine the predictive value of structural and functional parameters for disease progression. Baseline best corrected visual acuity (BCVA) and SRL SD are prognostic for disease progression (p < 0.001, p = 0.05). The presence of ellipsoid zone (EZ) loss is prognostic for future central retinal thickness (p < 0.01). We propose SRL SD, BCVA, and EZ loss as prognostic biomarkers and as possible outcome measures in future interventional studies in MacTel.
(© 2024. The Author(s).)
References: Retina. 2012 Nov-Dec;32(10):2001-5. (PMID: 22990322)
Retina. 2018 Jan;38 Suppl 1:S8-S13. (PMID: 28505012)
GMS Ophthalmol Cases. 2019 Aug 20;9:Doc29. (PMID: 31531275)
Retina. 2011 Oct;31(9):1848-55. (PMID: 21610563)
Br J Ophthalmol. 2021 May;105(5):735-740. (PMID: 32513667)
Retina. 2020 Nov 18;:. (PMID: 33230067)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT268-76. (PMID: 27409482)
PLoS One. 2013 Dec 11;8(12):e81499. (PMID: 24349078)
Br J Ophthalmol. 2021 Sep;105(9):1289-1296. (PMID: 30808615)
Br J Ophthalmol. 2022 Dec;106(12):1736-1741. (PMID: 34167944)
Retina. 2015 Nov;35(11):2161-2. (PMID: 26502006)
Ophthalmol Sci. 2022 Dec 08;3(2):100261. (PMID: 36846105)
Am J Ophthalmol. 2016 Oct;170:58-67. (PMID: 27496785)
Ophthalmic Epidemiol. 2010 Jan-Feb;17(1):66-73. (PMID: 20100102)
Invest Ophthalmol Vis Sci. 2019 Aug 1;60(10):3556-3562. (PMID: 31415079)
Retina. 2018 Jan;38 Suppl 1:S20-S26. (PMID: 28541959)
Am J Ophthalmol. 2016 Nov;171:101-112. (PMID: 27594138)
Sci Rep. 2023 Oct 9;13(1):16981. (PMID: 37813968)
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14354-9. (PMID: 23918361)
Dev Ophthalmol. 2016;56:146-58. (PMID: 27022942)
Invest Ophthalmol Vis Sci. 2023 Jul 3;64(10):21. (PMID: 37462978)
Am J Ophthalmol. 2008 Jan;145(1):169-175. (PMID: 17981256)
Ophthalmology. 1993 Oct;100(10):1536-46. (PMID: 8414413)
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3683-3689. (PMID: 28727884)
Graefes Arch Clin Exp Ophthalmol. 2022 Jan;260(1):121-132. (PMID: 34410484)
Ophthalmology. 2024 Feb;131(2):219-226. (PMID: 37739233)
Int Ophthalmol. 2019 Oct;39(10):2245-2256. (PMID: 30607862)
Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1825-9. (PMID: 17345090)
Ophthalmology. 2019 Apr;126(4):540-549. (PMID: 30292541)
Retina. 2015 Nov;35(11):2163-80. (PMID: 26428607)
Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834)
Prog Retin Eye Res. 2013 May;34:49-77. (PMID: 23219692)
Sci Rep. 2024 Feb 5;14(1):2933. (PMID: 38317017)
JAMA Ophthalmol. 2017 Mar 1;135(3):259-262. (PMID: 28097291)
Am J Ophthalmol. 2018 Oct;194:35-45. (PMID: 30026083)
فهرسة مساهمة: Keywords: Longitudinal; MacTel; Macular Telangiectasia Type 2; OCTA; Optical coherence tomography angiography; Progression
تواريخ الأحداث: Date Created: 20240727 Date Completed: 20240728 Latest Revision: 20240806
رمز التحديث: 20240806
مُعرف محوري في PubMed: PMC11283486
DOI: 10.1038/s41598-024-67801-4
PMID: 39068228
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-67801-4